Upper tract urothelial carcinoma - Renal and Urology News

Upper Tract Urothelial Carcinoma


Male ureters illustration

Evolving Strategies in the Management of Low-Grade UTUC

Upper tract urothelial cancer (UTUC) represents approximately 5%-10% of all urothelial cancers, although the incidence is increasing. Modifiable risk factors include exposure to toxins such as tobacco smoke, industrial toxins (including aromatic hydrocarbons, coal, coke, chlorinated solvents, and tars), arsenic, the analgesic phenacetin, and aristolochic acid. Produced by plants of the genus Aristolochia, aristolochic acid…

Jelmyto Approved for Low-Grade Upper Tract Urothelial Cancer

The Food and Drug Administration (FDA) has granted expedited approval of Jelmyto (mitomycin for pyelocalyceal solution; UroGen Pharma) for the treatment of adult patients with low-grade upper tract urothelial cancer (LG-UTUC). The approval was based on data from the ongoing open-label, single-arm, phase 3 OLYMPUS study that assessed the efficacy of Jelmyto in 71 adults…
Next post in Upper tract urothelial carcinoma